

Piccinni C¹, Antonazzo IC^{2,3}, Maggioni AP¹, Pedrini A¹, Calabria S¹, Ronconi G¹, Dondi L¹, Martini N¹, Roberto G², Sampietro T³, Sbrana F³, Dal Pino B³, Bigazzi F³, Lo Surdo G⁵, Volpi E⁵, Biagini S⁵, Gini R²

1. Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma, Italy; 2. Epidemiology Unit, Regional Agency for Healthcare Services of Tuscany, Florence, Italy; 3. Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 4. Lipoapheresis Unit, reference center for diagnosis and treatment of inherent dyslipidemias – Fondazione Toscana Gabriele Monasterio, Pisa, Italy; 5. Hospital pharmacy, Fondazione Toscana Gabriele Monasterio, Massa, Italy

OBJECTIVE

The aims of this study were to **characterise patients starting a PCSK9i therapy** in Tuscany during the first reimbursement year and to describe their pattern of use.


METHODS

Patients on PCSK9-inhibitor administration in Tuscany (3.7 million inhabitants) from 07/2017 to 06/2018 were selected from **regional healthcare administrative databases**. Concomitant use of Lipid-Lowering-Therapies (LLTs), adherence and persistence (no gap ≥ 60 days between subsequent prescriptions) during the six-months preceding the first PCSK9-inhibitor dispensing, as well as comorbidities since 1996, were described. In the first six-months of PCSK9-inhibitor treatment, adherence (proportion of days covered $\geq 75\%$), persistence (no gap ≥ 30 days) were assessed.

RESULTS

New users of PCSK9-inhibitor were 269 (176 evolocumab, 93 alirocumab) (Fig 1). The monthly occurrence of PCSK9 inhibitors' new users showed an initial increase (from July 2017 to February 2018), followed by a decrease ending in a plateau in the last observed period (Fig 2). We have detected two peaks in November 2017 and in February 2018, corresponding to the end of trials testing evolocumab in Tuscanian patients (i.e. AMG145-20110271; AMG145-20120138; AMG145-20120332 and AMG145-20140316). Patients (mean age of 59.1 years) were mainly male (71.0%) in secondary prevention (70.2%) and affected by familial hypercholesterolemia (53.5%). 66 patients (24.5%) had diabetes and 12 (4.5%) chronic renal failure. **In the six-months preceding the first PCSK9-inhibitor dispensing, 61.3% of patients received at least one prescription of ezetimibe or high intensity statins** and 45.7% were persistent to these drugs (Tab 1). During follow-up period (analysed 266 of 269 patients), **80% of patients were adherent to PCSK9-inhibitor and 73% were persistent** (Tab 2).

Fig 1 - Selection of new PCSK9i users




Tab 1 - Lipid lowering therapy in the 6 months previous the PCSK9 inhibitors initiation

	Primary prevention N (%)	Secondary prevention N (%)	Total N (%)
PCSK9 inhibitors' new users	80 (100)	189 (100)	269 (100)
Use of LLT during the previous 6 months			
No LLTs	29 (36.3)	31 (16.4)	60 (22.3)
At least one prescription of LLT included in reimbursement criteria*	37 (46.3)	128 (67.7)	165 (61.3)
Only prescription of other LLTs	14 (17.5)	30 (15.9)	44 (16.4)
Persistence to LLT use			
LLT included in reimbursement criteria*	22 (27.5)	101 (53.4)	123 (45.7)
Other LLTs	8 (10.0)	17 (9.0)	25 (9.3)
Patterns of LLT use			
Ezetimibe + moderate/low intensity statin [§]	13 (16.3)	40 (21.2)	53 (19.7)
Ezetimibe in monotherapy	8 (10.0)	37 (19.6)	45 (16.7)
Ezetimibe + high intensity statins [^]	9 (11.3)	39 (20.6)	48 (17.8)
High intensity statins [^] in monotherapy [^]	7 (8.8)	12 (6.3)	19 (7.1)
Other LLTs			
Moderate/low intensity statins [§] in monotherapy	6 (7.5)	12 (6.3)	18 (6.7)
Omega 3 in monotherapy	5 (6.3)	8 (4.2)	13 (4.8)
Fibrates in monotherapy	1 (1.3)	4 (2.1)	5 (1.9)
Bile acid sequestrants in monotherapy		1 (0.5)	1 (0.4)
Other LLT combinations	2 (2.5)	5 (2.6)	7 (2.6)

Legend: LLT=lipid lowering therapy; *reimbursement criteria= "prior treatment with high intensity statin agent and ezetimibe, or ezetimibe monotherapy in case of statins intolerance, for at least 6 months; ^ high intensity statins: atorvastatin (40 and 80 mg), rosuvastatin (20 and 40 mg); § moderate/low intensity statin: atorvastatin (10 and 20 mg), rosuvastatin (5 and 10 mg), simvastatin, lovastatin, pravastatin, fluvastatin

Fig 2 - Temporal trend of PCSK9 inhibitor starting in Tuscany Region from July 2017 to June 2018



Tab 2 - PCSK9 inhibitor patterns of use in the first 6 months of treatment

	Evolocumab N (%)	Alirocumab N (%)	Total N (%)
PCSK9 inhibitors' new users	175 (100)	91 (100)	266 (100)
Adherence (PDC)^a			
<75	34 (19.4)	19 (20.9)	53 (19.9)
≥ 75	141 (80.6)	72 (79.1)	213 (80.1)
Persistence and continuity^b			
Persistent for 6 months	127 (72.6)	68 (74.7)	195 (73.3)
Interruption followed by new dispensing	36 (20.6)	15 (16.5)	51 (19.2)
Interruption after more than one dispensing	9 (5.1)	7 (7.7)	16 (6.0)
Interruption after the first dispensing	3 (1.7)	1 (1.1)	4 (1.5)
Switch^c			
	1 (0.6)	0 (0.0)	1 (0.4)

Legend: PDC= Proportion of Days Covered (i.e. the sum of days covered by medications divided by number of days in the follow-up period); a) PDC ≥ 75 was considered as indicator of good adherence to the treatment. b) Persistence has been defined as absence of a gap longer than 30 days between the end of the duration of a dispensing and the new dispensing (discontinuation) or end of follow-up (interruption).. c) Change between the two active substances during the follow-up

CONCLUSIONS

During the first-year of availability, **the administration of PCSK9-inhibitors appears below expectations**. Patients were mainly in secondary prevention and had been previously persistent to LLTs. During follow-up, **the PCSK9-inhibitor monotherapy showed high adherence and persistence**. This real-world study sets the stage for future longer-term investigations useful to improve our knowledge on the appropriateness, drug access and public healthcare sustainability of PCSK9-inhibitors.